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The combination of high-dose melphalan supported by autologous stem cell transplantation (ASCT) has significantly increased response rate and survival in patients with multiple myeloma (MM), and is now considered the new standard of care for patients eligible to the transplant procedure. 1 The peripheral blood stem cells (PBSC) collection is preceded by the induction chemotherapy to decrease the tumor mass within the bone marrow, also participating on in vivo purging to decrease the contamination of the stem cell collection with tumor cells. Mobilization and cytapheresis generally takes place following cycle 3 or 4 of induction, and steady state remains considered the easiest and safest way to collect PBSC. 2 The VAD (vincristin-adriamycin-dexamethasone) was the historical induction regimen, before the era of targeted novel agents; 3 however, the bortezomib-based induction therapy has become the gold standard, with increased response rates and prolonged progressionfree survival. 1 The previous studies showed that bortezomib had no toxic effects on stem cells, megakaryocytes or neutrophil precursors, nor on the quality of PBSC as defined by engraftment time, and causes only transient and reversible thrombocytopenia and neutropenia. 4 Nonetheless, we have noticed in-house that the amount of days of collection may increase following bortezomib-dexamethasone (VD) induction as compared with VAD, although the final harvested PBSC amount appeared identical. We have therefore hypothesized that bortezomib-based induction therapy decreased the quality of harvest during the mobilization process, and that might correlate to an increased days of collection and consequently impacted significantly on the cost of the procedure.
We conducted a retrospective study on 112 newly diagnosed MM patients 5 collected from 2006 to 2010 at the Apheresis Department, EFS (Etablissement Franc¸ais du Sang) Nord de France that have received VD (N ¼ 70) or VAD (N ¼ 42) induction regimens. A third group was constituted of 11 patients treated with VTd (bortezomib-thalidomide-low-dose dexamethasone) for use as comparison, as this group was collected using high-dose cyclophosphamide (hdCyclo). 6, 7 We have excluded patients who might have received other bortezomib-based regimens and who were not collected at front line to homogenize our studied population. The median age at collection was 57, 62 and 60 years; sex ratio was 1.64, 1.21 and 1.20; and median weight was 73, 65 and 72 kg for the three groups, respectively. In all, 9%, 17% and 11% had creatinin 420 mg/l, and 59%, 60% and 57% had ISS 2 þ 3, respectively, at diagnosis (P ¼ NS). In all, 3% of patients had platelets o100 g/l in the former group and none in the remaining two groups, and 2%, 7% and 4% had hemoglobin o10 g/dl, respectively, at the time of collection (P ¼ NS). The median number of cycles was 4 (range 1-5) in either group, VD or VAD. The median number of cycles was 3 (range 1-4) in the VTD group. As expected, the response rates were greater in the bortezomib-based induction regimen groups, 79 and 89%, versus 60% using VAD (P ¼ 0.0095) before ASCT. The steady state procedure for the first two groups and the hdCyclo procedure were conducted as published. 2 All harvests were performed on SPECTRA, MNC program (Terumo BCT, Bourg La Reine, France). CFU-GM (colony-forming unit granulocyte and macrophage) was determined as previously published.
8 CD34 þ cells (circulating or in the cytapheresis product) were enumerated on multicolor flow cytometry single platform on a XLMCL Coulter EPICS Cytometer (Beckman Coulter France S.A.S, Villepinte, Roissy CDG Cedex, France), in accordance with the International Society of Hemotherapy and Graft Engineering protocols recommendations. 9, 10 This study was approved by the Ethical Committee of Human Experimentation in Lille, France, and collection of patients data was in accordance with the Helsinki Declaration.
Overall, the mobilization of circulating CD34 þ cells was lower in the VD group as compared with the VAD (Table 1) . We then sought to study whether the lower mobilization rate in the VD group negatively impacted the quantity of PBSC collected during cytapheresis. We observed that the yield of daily harvested CD34 þ cells and CFU-GM count were also lower in the VD group as compared with the VAD (Table 1) , irrespective of the response rate status. The median ( ± s.e.) daily harvest of responders to VD was greater than non-responders, 6.3±0.9 versus 3.6±2.5, although not significant (P ¼ 0.08); but clearly inferior to VAD, 7.8 ± 3.5 and 8.3 ± 2.0, respectively. We also noticed insufficient daily harvest (o2 Â 10 6 CD34/kg) and a lower rate of very satisfactory daily harvests (44 Â 10 6 CD34/kg) in the VD group as compared with the VAD (Figure 1a , Table 1 ). 10 Similar results were observed using the CFU-GM counts. Furthermore, more patients needed more than 2 days of harvest in the VD versus VAD group (Figure 1b, Table 1 ). In contrast, the VTd group had a greater mobilization and daily harvest using hdCyclo, which turned into no insufficient daily harvest and a higher rate of very satisfactory daily harvest, using either CD34/kg or CFU-GM count. We have looked at the response rate that can affect the mobilization and collection yield, being a potential confounding factor to eliminate, but the response rate after induction was clearly superior in the VD group. There was no increase in the infection rate, especially related to dexamethasone. Finally, the percentage of patients with hemoglobin o10 g/dl and platelets o100 g/l at the harvesting time, both criteria considered as predictive markers of poor cytapheresis efficiency, did not differ in the VD and VAD groups. 11 There is no clear explanation on why bortezomib has some negative impact on mobilization and collection. Bortezomib is not known as a myelotoxic drug, which could negatively affect Accepted article preview online 25 May 2012; advance online publication, 19 June 2012 hematopoiesis; and the negative impact of bortezomib on PBSC collection remains largely unexplored and unpublished. In this study, we have focused thus on daily harvest to avoid global analysis, knowing that the possibility to increase amount of days of collection might neutralize the effect of bortezomib, hingeing on increased cost. 12 We have then sought to demonstrate that this increase in days of harvest was of great discomfort for the patients, and certainly impacted the cost for the procedure. In our series, 129 versus 66 days of harvest were needed in the VD and VAD groups, respectively. Overall, the mean cost of mobilization was 4503.7 and 3184.4 euros for the two groups, respectively; for example, 1.41 times more expensive in the VD group. The cost of mobilization also further increased related to the increase of days of harvest in the VD group, and thus the increased G-CSF injections (B1871.8 euros with 5 days). A greater percentage of patients in the VD group were collected after the cycle 4 to complete the expected total amount of harvested cells, 17% versus 7%, respectively (Table 1) .
Interestingly, the quality of mobilization of the engraftment and the time to engraftment did not differ in the three groups, as exemplified by the clonogenicity (CFU-GM/100 CD34 ratio; Table 1 ). We have also not noticed any significant difference regarding the time to engraftment, the time to recovery of 41 g/l leukocyte, 40.5 g/l neutrophil and 450 g/l platelet counts; and the amount of red blood cell and platelet transfusions during ASCT procedure were not significantly different between the three groups (data not shown). Although CD34 þ mobilization and PBSC collection was lower following VD, it did not lead to engraftment failure or delay, nor did it alter clonogenicity; for example, considered as satisfying by Affsaps (French Sanitory Authority).
The combination of IMiDs (thalidomide, lenalinomide) with bortezomib-based induction regimen is currently considered a standard of care before performing front line transplant procedure, and will likely further alter the quality and quantity of the mobilization and collection processes. There is therefore a need to develop and to explore new agents for mobilization. Although certain protocols currently explore in vivo purging before mobilization and collection with hdCyclo, other protocols study plerixafor (anti-CXCR4 antibody). 2 We have confirmed that the yield of PBSC collected following hdCyclo is by far greater than the steady state procedure in this study in a small cohort. The quality and quantity of harvest might thus improve using new mobilizing techniques in the future; although the cost will certainly remain an /kg CD34 þ stem cells is generally the minimal threshold to obtain a rapid and durable engraftment, we observed that 35% of MM in the bortezomib-based regimen group had insufficient daily harvest to perform a graft, significantly lower than MM in the VAD-based regimen group, 12% (P ¼ 0.007). Consequently, the patients needed an increased number of days of PBSC collect. Taking in account the 4.10 6 /kg CD34 þ stem cells cutoff, considered as the minimal amount to perform two autografts, we also noticed that only 29% of MM in the bortezomib-based regimen group had a sufficient daily collect as compared with 59% in the VAD-based regimen group (Po0.0001). (b) Number of days of PBSC harvest. Numbers of days needed to collect PBSC to perform at least one autologous PBSC transplantation in the bortezomib-based regimen and the VAD groups. The figure shows that 1 day of PBSC collection is sufficient in most of MM in the VAD group, whereas 2 days was required in the majority of patients in the bortezomib-based regimen group. This finding contributes to the increased cost of PBSC collect in the MM treated with bortezomib-based induction regimen in front line MM. Abbreviations: CFU-GM, colony-forming unit granulocyte and macrophage; PBSC, peripheral blood stem cell; VAD, vincristin-adriamycin-dexamethasone; VD, bortezomib-dexamethasone; VTd, bortezomib-thalidomide-dexamethasone.
Letters to the Editor issue. The use of these expensive techniques in either routine practice or only in case of steady state collection failure remains unanswered. The purpose of this study was not to demonstrate that we should start over with the VAD induction regimen, while the efficiency of bortezomib-based induction regimens has been largely demonstrated in several multicentric, randomized trials. 1, 13, 14 As a matter of fact, we sought to demonstrate that bortezomib-based induction regimens alter mobilization of stem cells and collection of PBSC, and that it has a negative impact on patients discomfort, on staff availability, on scheduling at the EFS and finally it clearly negatively impact on the cost of the overall pre-transplant procedure. This data emphasize the need to develop alternative options to the steady state procedure. These results need to be confirmed in larger studies.
We reported an increase difficulty of mobilization and harvesting in bortezomib-based induction therapy in the transplant procedure in this study. New techniques to proceed to stem cell collection should be considered in transplant-eligible patients treated with bortezomib-based induction therapy.
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